Fosun was founded in 1992. After more than 30 years of development, Fosun has become a global innovation-driven consumer group. Adhering to the mission of creating happier lives for families worldwide, Fosun is committed to creating a global happiness ecosystem fulfilling the needs of families in Health, Happiness, and Wealth. In 2007, Fosun International was listed on the main board of the Hong Kong Stock Exchange (stock code: 00656.HK). As of 30 June 2026, Fosun International’s total assets amounted to RMB712.3 billion, with its latest MSCI ESG rating at AAA, the highest rating.

Long‑standing Commitment to the Two Core Drivers of “Globalization” and “Innovation”

Rooted in China, Fosun has been developing globally while remaining committed to its two key drivers of “globalization” and “innovation”. Fosun is one of the few Chinese companies that is equipped with global operational and investment capabilities, and has built strong capabilities in technology and innovation.

Fosun’s globalization journey began with its listing in 2007. Over the past 19 years, Fosun has established a business presence in more than 40 countries and regions around the world. In the first half of 2026, overseas revenue accounted for 56.5% of the Group’s total revenue. The model of “global organization + local operations” has entered the 3.0 era of “Combining Global Resources with China’s Capabilities”. By deeply integrating China’s manufacturing capabilities, service capabilities, and innovation dividends with the global market, the Group is building end-to-end operational capabilities across its core businesses, spanning “global research and development (R&D), global supply chain, and global commercialization”. Fosun’s globalization strategy means more than just “two-way engagement” between the global and Chinese markets. It extends to the endogenous development of its ecosystem enterprises both domestically and internationally, encouraging them to actively expand their businesses beyond their home markets.

Innovation serves as another key driver of Fosun’s development. In the first half of 2026, Fosun invested RMB4.2 billion in technology innovation, representing a year-on-year increase of 16.7%. Its global innovation system integrating “independent R&D + investment incubation + ecosystem collaboration” continued to mature, delivering a series of globally competitive innovations. Over the years, Fosun has been committed to applying innovative technologies in product iteration, blockbuster product development, customer service, and customer engagement. By collaborating with governments at various levels, universities, and scientific research institutions, Fosun has fostered the in-depth integration of industry, academia, and research to maintain its cutting-edge competitiveness.

In the era of artificial intelligence (AI), Fosun fully embraces AI to advance the transition from “business + AI” to “AI + business”, aiming to lead the industry in AI adoption. In terms of pharmaceutical R&D, Fosun Pharma completed the upgrade of its PharmAID® V2.0 to support AI-powered product development across the full lifecycle, from early-stage R&D to product launch. Leveraging its “AI for Science” platform, Henlius’ next-generation recombinant human hyaluronidase (rHuPH20) injection shortened the enzyme-molecule design cycle from 18 months to 5 months. “AI G.O” in Fosun’s Tourism segment provides 24/7 online, multilingual, and personalized intelligent butler service. It has been successfully deployed at Atlantis Sanya and several Club Med resorts in Chinese mainland, with broader deployment under way. Fosun Insurance Portugal (Fidelidade) is extending AI applications to decision-making across its core businesses, while claims automation continues to improve.

Focusing on Core Industries: Pharmaceuticals and Healthcare, Insurance and Finance, and Cultural Tourism and Consumer Businesses

Powered by its twin-driver strategy of “industry operations + industrial investment”, Fosun continues to focus on core industries such as pharmaceuticals and healthcare, insurance and finance, as well as cultural tourism and consumer businesses. In the first half of 2026, the total revenue of its subsidiaries — Fosun Pharma, Yuyuan, Fosun Insurance Portugal (Fidelidade), and Fosun’s Tourism segment — accounted for 73.5% of the Group’s total revenue.

The pharmaceutical business encompasses three major areas: biopharmaceuticals, devices & diagnostics, and healthcare services. Targeting unmet medical needs, Fosun Pharma has established a deep presence in core therapeutic areas such as oncology, immunology and inflammation, and neurodegenerative diseases, while actively expanding into cardiometabolic diseases and rare diseases. This approach enables the development of high valued competitive pipelines and comprehensive healthcare solutions. Meanwhile, it continues to consolidate its core technical platforms including antibodies and antibody-drug conjugates (ADCs), small molecules and cell therapies, while expanding into cutting-edge therapeutic modalities such as radiopharmaceuticals and small nucleic acids. Its innovative products are now available in more than 90 countries and regions worldwide. In the first half of 2026, 20 indications of 7 innovative drugs were approved for launch both domestically and overseas. HANSIZHUANG, HLX43, and other marketed and pipeline innovative drugs have delivered several “world’s first” breakthroughs.

In insurance and finance, Fosun has built a global insurance and asset management ecosystem, drawing on its long-standing expertise in the insurance industry. Fidelidade has long maintained its leading position in the Portuguese market (with a market share of more than 30%), while its international business accounted for 26.7% of its consolidated total business. Peak Reinsurance sustained solid growth. Fosun United Health Insurance and Pramerica Fosun Life Insurance have entered a phase of profitable growth, with both the scale and quality of their profits reaching new heights in the first half of 2026.

In the cultural tourism and consumer businesses, Yuyuan serves as the core platform, leveraging oriental lifestyle aesthetics to lead the trend of Chinese cultural revival. It has built a household consumer portfolio spanning jewelry and fashion, cultural retail, cultural food and dining, and national watch brands. The Yuyuan Lantern Festival, a national intangible cultural heritage project, and renowned China time-honored brands such as Laomiao, Songhelou, Nanxiang Steamed Bun Restaurant, and Shede Spirits, have accelerated their overseas expansion, bringing high-quality oriental lifestyle experiences to families around the world. The Tourism business has developed three major product lines targeting global and Chinese markets: “Super Resort”, “Super Resort Complex”, and “Super Culture and Tourism Mall”, delivering high-quality vacation destinations and experiences for families across the globe. Club Med has established a sales network spanning more than 40 countries and regions across six continents and operates 69 premium resorts worldwide. Atlantis Sanya has become an iconic destination for Hainan’s tourism sector and maintains high occupancy throughout the year.

Upholding the Corporate Values of “Self-improvement, Teamwork, Performance, and Contribution to Society”

Since its establishment more than 30 years ago, Fosun has consistently upheld its corporate values of “Self-improvement, Teamwork, Performance, and Contribution to Society”. Fosun has diligently embraced its corporate social responsibility, achieving outstanding performance in environmental, social, and governance (ESG) practices. Fosun International’s MSCI ESG rating has been upgraded to the highest rating of AAA, and it has once again been included in S&P Global’s Sustainability Yearbook 2026 and ranked among the top 1% in the Sustainability Yearbook (China Edition) 2026.

Fosun Foundation carries out philanthropic initiatives across global emergency relief, rural revitalization, healthcare support, youth entrepreneurship, education, and culture & art, etc. Since the launch of the Rural Doctors Program at the end of 2017, the program has covered 78 counties in 16 provinces, cities, and autonomous regions across the country, supporting 25,000 rural doctors and benefiting 3 million rural families. In global public health, as of 30 June 2026, Fosun Pharma had cumulatively supplied more than 460 million vials of artesunate for injection worldwide, saving more than 92 million patients with severe malaria.